Alzheimer's disease and melatonin

Etsuro Matsubara, Mikio Shoji, Tetsuro Murakami, Takeshi Kawarabayashi, Koji Abe

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

Original languageEnglish
Pages (from-to)395-398
Number of pages4
JournalInternational Congress Series
Volume1252
Issue numberC
DOIs
Publication statusPublished - Jun 1 2003

Fingerprint

Melatonin
Alzheimer Disease
Neuroprotective Agents
Amyloidosis
Amyloid
Oxidants
Oxidative Stress
Therapeutics
Neuroprotection

Keywords

  • Alzheimer's disease
  • Amyloid β
  • Anti-amyloidogenic properties of melatonin
  • Antioxidant properties of melatonin
  • Melatonin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Matsubara, E., Shoji, M., Murakami, T., Kawarabayashi, T., & Abe, K. (2003). Alzheimer's disease and melatonin. International Congress Series, 1252(C), 395-398. https://doi.org/10.1016/S0531-5131(03)00019-0

Alzheimer's disease and melatonin. / Matsubara, Etsuro; Shoji, Mikio; Murakami, Tetsuro; Kawarabayashi, Takeshi; Abe, Koji.

In: International Congress Series, Vol. 1252, No. C, 01.06.2003, p. 395-398.

Research output: Contribution to journalArticle

Matsubara, E, Shoji, M, Murakami, T, Kawarabayashi, T & Abe, K 2003, 'Alzheimer's disease and melatonin', International Congress Series, vol. 1252, no. C, pp. 395-398. https://doi.org/10.1016/S0531-5131(03)00019-0
Matsubara E, Shoji M, Murakami T, Kawarabayashi T, Abe K. Alzheimer's disease and melatonin. International Congress Series. 2003 Jun 1;1252(C):395-398. https://doi.org/10.1016/S0531-5131(03)00019-0
Matsubara, Etsuro ; Shoji, Mikio ; Murakami, Tetsuro ; Kawarabayashi, Takeshi ; Abe, Koji. / Alzheimer's disease and melatonin. In: International Congress Series. 2003 ; Vol. 1252, No. C. pp. 395-398.
@article{9b287ef6d1ed40e2ae9143ac7cd6f295,
title = "Alzheimer's disease and melatonin",
abstract = "Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.",
keywords = "Alzheimer's disease, Amyloid β, Anti-amyloidogenic properties of melatonin, Antioxidant properties of melatonin, Melatonin",
author = "Etsuro Matsubara and Mikio Shoji and Tetsuro Murakami and Takeshi Kawarabayashi and Koji Abe",
year = "2003",
month = "6",
day = "1",
doi = "10.1016/S0531-5131(03)00019-0",
language = "English",
volume = "1252",
pages = "395--398",
journal = "International Congress Series",
issn = "0531-5131",
publisher = "Elsevier BV",
number = "C",

}

TY - JOUR

T1 - Alzheimer's disease and melatonin

AU - Matsubara, Etsuro

AU - Shoji, Mikio

AU - Murakami, Tetsuro

AU - Kawarabayashi, Takeshi

AU - Abe, Koji

PY - 2003/6/1

Y1 - 2003/6/1

N2 - Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

AB - Melatonin has a two different mechanism of action to prevent pro-amyloidogenic environment that leads to Alzheimer's amyloid β (Aβ) amyloidosis: (1) anti-amyloidogenic and (2) anti-oxidant properties. The former causes the reduction of the β-sheet-rich conformer which becomes aggregated and neurotoxic, contributing to neuroprotection. The latter also results in the reduction of neuronal damage mediated by Aβ-mediated oxidative stress. These strong neuroprotective effects may bear relevance to pathogenesis and therapy of Alzheimer's disease (AD). This review focuses on melatonin as a therapeutic agent for Alzheimer's disease.

KW - Alzheimer's disease

KW - Amyloid β

KW - Anti-amyloidogenic properties of melatonin

KW - Antioxidant properties of melatonin

KW - Melatonin

UR - http://www.scopus.com/inward/record.url?scp=4644249295&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4644249295&partnerID=8YFLogxK

U2 - 10.1016/S0531-5131(03)00019-0

DO - 10.1016/S0531-5131(03)00019-0

M3 - Article

AN - SCOPUS:4644249295

VL - 1252

SP - 395

EP - 398

JO - International Congress Series

JF - International Congress Series

SN - 0531-5131

IS - C

ER -